Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 52Multiple Myeloma 42Lymphoma 42Neoplasm Metastasis 41Lung Neoplasms 38Breast Neoplasms 38Prostatic Neoplasms 32Carcinoma, Non-Small-Cell Lung 31Leukemia, Myeloid, Acute 30Colorectal Neoplasms 28Melanoma 27Ovarian Neoplasms 26Hematologic Neoplasms 25Urinary Bladder Neoplasms 22Pancreatic Neoplasms 22Lymphoma, Non-Hodgkin 21Glioma 21Carcinoma, Renal Cell 20Sarcoma 18Myelodysplastic Syndromes 16Burkitt Lymphoma 16Triple Negative Breast Neoplasms 15Stomach Neoplasms 15Neuroblastoma 14Colonic Neoplasms 14Brain Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 13Fallopian Tube Neoplasms 13

Interventions

Specimen Handling 1Human Papillomavirus Recombinant Vaccine nonavalent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Human Papillomavirus-Related Carcinoma × 30 days × Clear all
NCT05985681 2026-05-13

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

National Cancer Institute (NCI)

Phase 1 Recruiting
18 enrolled

Human Papillomavirus-Related Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡